Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex
Launched by HENRY C. LIN, MD · Aug 10, 2009
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
The investigator will assess the prevalence and role of abnormal gut microbial fermentation among Veterans with GWS and investigate the efficacy of diagnostic and treatment strategies directed at indigenous gut microbes in the management of GWS.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Gulf War Veterans meeting the 1994 Centers for Disease Control and Prevention (CDC) criteria for the diagnosis of Chronic Fatigue Syndrome(CFS), i.e \> six months of one or more symptoms from at least two of the following three clusters: general fatigue, mood and cognitive abnormalities, and musculoskeletal pain
- • Must be under the care of a primary physician and have had a previous diagnosis of Gulf War-related illness or GWS and have medical records documenting investigations to rule out other causes of fatigue
- • Minimum of the following laboratory screening tests: complete blood count with leukocyte differential, erythrocyte sedimentation rate, serum electrolytes, calcium, glucose, blood urea nitrogen, creatinine,urinalysis, and thyroid function tests
- • Subjects must also have a GI consult first as part of routine care to confirm eligibility and availability
- • Patients with Irritable Bowel Syndrome (IBS), fibromyalgia (FM), anxiety or depression will not be excluded, but will be identified for subgroup analysis
- • Healthy controls will be screened with complete blood count (CBC) and comprehensive metabolic panel to confirm eligibility
- Exclusion Criteria:
- • History of peptic ulcer, inflammatory bowel disease, diabetes, cirrhosis, rheumatoid arthritis, lupus, narcotic dependence,celiac disease, tropical sprue, bowel resection(including gastric, small bowel or colon; but gallbladder surgery or appendectomy are NOT exclusion criteria)
- • Patients with chronic illness (HIV, tuberculosis)
- • Pregnant or breast-feeding, psychotic depression, bipolar disorder, schizophrenia, eating disorders
- • Healthy subjects will be excluded if their questionnaire indicated abnormal symptom profile
About Henry C. Lin, Md
Dr. Henry C. Lin, MD, is a distinguished clinical trial sponsor dedicated to advancing medical research and enhancing patient care through innovative clinical studies. With a robust background in clinical medicine and a commitment to evidence-based practices, Dr. Lin leads trials that focus on developing cutting-edge therapies and interventions across various medical fields. His expertise in clinical trial design and management ensures rigorous adherence to regulatory standards and ethical considerations, fostering collaborations that drive scientific discovery and improve health outcomes. Dr. Lin's work exemplifies a commitment to translating research findings into tangible benefits for patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Albuquerque, New Mexico, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials